S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,170.08 +0.42%
Next Bullish Trade
Sign in
KLRS

Kalaris Therapeutics, Inc. KLRS

$4.38 -0.23 (-4.99%)
Neutral · -0.36σ Grade A
+ Compare Open in Sniper

Price chart

Timeframe
Range
Fundamentals · free Click ▲ earnings markers (daily) for the day's move

Loading…

Latest bar · KLRS

Momentum reads · latest daily bar
Last
$4.38
-0.23 (-4.99%)
Mkt cap
$104M
Healthcare
RSI(14)
45.2
neutral
Stochastic %K
60.3
neutral
MFI(14)
96.6
overbought
ADX(14)
13.9
weak trend

Green means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.

Financial overlay · last 12 quarters

The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.

QuarterRevenue Net incomeOp income FCFNet margin Op margin
2026-03-31 — $-0.0B $-0.0B $-0.0B — —
2025-12-31 — $-0.0B $-0.0B $-0.0B — —
2025-09-30 — $-0.0B $-0.0B $-0.0B — —
2025-06-30 — $-0.0B $-0.0B $-0.0B — —
2025-03-31 — $-0.0B $-0.0B $-0.0B — —
2024-12-31 $nanB $nanB $nanB $nanB nan% nan%

Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.

Compare KLRS vs peers

Line KLRS up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.

Comparing KLRS UNH×
Sector peers + LLY + JNJ + MRK + ABBV + PFE + TMO
Popular + AAPL + MSFT + NVDA + AMZN + GOOG + META + TSLA + AVGO
Matchups NVDA · AMD · AVGO · SMCI · MU AAPL · MSFT · GOOG · META · AMZN JPM · GS · MS · BAC · C TSLA · RIVN · LCID · GM · F XOM · CVX · OXY · COP
Verdict
Weighted score 0-100 across 2 tickers · best in green
#2
KLRS
score 33.3
4/5 inputs
Catastrophic momentum score of zero driven by negative 63% drop from 52-week high destroys overall ranking.
value 50quality 17momentum 0sentiment 67
#1
UNH
score 62.5
5/5 inputs
Perfect momentum score of 100 from 35% quarterly gain and 27% YTD return dominates KLRS decisively.
value 50growth 50quality 83momentum 100sentiment 33
KLRS
Kalaris Therapeutics, Inc.
$4.38
-4.99%
Snapshot
Price 4.38
Day % -4.99
1M % 0.23
3M % -33.54
YTD % -47.23
Market cap 104210184.0
ADV ($) 1112419.289065361
Beta —
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % -3.68
Dist ATR (σ) -0.36
OdysseyHQ grade A
Confluence 5
Valuation
P/E (ttm) —
P/E (fwd) -2.693313
P/S —
EV/EBITDA —
P/B 1.4688128
FCF yield -0.2612
PEG —
Growth
Revenue yoy —
EPS yoy —
FCF yoy —
Revenue trend 8Q
Quality
Gross margin 0.0
Operating margin 0.0
Net margin 0.0
ROE -0.66598
ROA -0.27966
Debt / Equity 0.02
Interest cov. -29.1
Technicals
RSI(14) 45.2
MACD signal neutral
vs 50-DMA -5.89
vs 200-DMA -34.31
vs 52w high -63.13
HV-30 64.7
Sentiment
Analyst rec 1.5
Target upside 327.27
Insider buy-sell 90d 8
Risk
Short interest 6.0399998
Days to cover 6.12
Next earnings —
Full KLRS dashboard →
UNH
UnitedHealth Group Incorporated
$426.09
+0.64%
Snapshot
Price 426.09
Day % 0.64
1M % 4.52
3M % 34.67
YTD % 26.66
Market cap 386951249920.0
ADV ($) 3118003879.2817383
Beta 0.633
OdysseyHQ zone
Current zone Neutral
Dist 21-EMA % 1.78
Dist ATR (σ) 0.6
OdysseyHQ grade C
Confluence 3
Valuation
P/E (ttm) 32.060947
P/E (fwd) 19.240608
P/S 0.85964525
EV/EBITDA 17.696
P/B 3.9526708
FCF yield 0.0588
PEG 1.42
Growth
Revenue yoy 0.004
EPS yoy 0.615
FCF yoy —
Revenue trend 8Q
Quality
Gross margin 0.19514
Operating margin 0.071329996
Net margin 0.03137
ROE 0.14152999
ROA 0.04382
Debt / Equity 0.69
Interest cov. 4.67
Technicals
RSI(14) 57.9
MACD signal neutral
vs 50-DMA 5.76
vs 200-DMA 24.8
vs 52w high -7.7
HV-30 26.9
Sentiment
Analyst rec 1.59259
Target upside 10.69
Insider buy-sell 90d 23
Risk
Short interest 2.26
Days to cover 2.55
Next earnings 2026-07-16
Full UNH dashboard →

Earnings replay · last 5 reports

How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.

DateEPS actual EPS estSurprise Next-day
2026-05-12 -0.46 -0.52 +12.1% +0.8%
2026-03-17 -0.44 -0.55 +20.0% -11.6%
2025-11-12 -0.64 -0.61 -4.5% +7.5%
2025-08-13 -0.61 -0.52 -17.3% -0.4%
2025-05-14 -2.52 -0.77 -225.2% +4.7%

Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.

Peer comparison · Healthcare

Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.

Ticker ⇅ Mkt cap ⇅ P/E ⇅ Fwd P/E ⇅ P/S ⇅ EV/EBITDA ⇅ P/B ⇅ Gross M ⇅ Rev gr ⇅ EPS gr ⇅ FCF yld ⇅
KLRS ★ $0B — -2.7 — — 1.5 — — — -26.12%
LLY $1,051B 41.8 26.3 14.6 30.1 33.8 82.8% 55.5% 169.9% 0.87%
UNH $387B 32.1 19.2 0.9 17.7 4.0 19.5% 0.4% 61.5% 5.88%
JNJ $609B 29.3 19.7 6.2 18.4 7.5 68.1% 6.6% -1.0% —
MRK $315B 36.0 13.2 4.8 12.1 6.9 76.7% 4.9% — 4.46%
ABBV $450B 124.8 15.6 7.2 17.2 -67.6 72.0% 12.4% -46.2% 4.63%
PFE $143B 19.1 8.8 2.3 7.6 1.6 74.8% 5.4% -10.1% 8.67%
TMO $198B 29.2 19.5 4.4 21.1 3.8 40.9% 6.2% 11.3% 2.79%

Auto-seeded from sector. Click any ticker to switch.

Ownership

Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.

Top institutional holders

Top-10 concentration: 71.95%

HolderShares% out
Samsara BioCapital, LLC 12,948,081 54.42%
RTW Investments LP 1,300,000 5.46%
Paradigm Biocapital Advisors LP 700,000 2.94%
Alyeska Investment Group, L.p. 572,687 2.41%
Siren, L.L.C. 435,798 1.83%
Ikarian Capital, LLC 360,000 1.51%
Propel Bio Management, LLC 295,771 1.24%
Vanguard Capital Management LLC 255,348 1.07%
Kalehua Capital Management LLC 135,585 0.57%
Raymond James Financial, Inc. 118,887 0.50%

Insider activity · 90d

8 buys / 0 sells · ratio 8.0 · Finnhub

  • Ferrara Napoleone BUY 9,000
  • Dybbs Michael BUY 9,000
  • Jovan-Embiricos Morana BUY 9,000
  • Hallal David BUY 9,000
  • ADAMIS ANTHONY P BUY 9,000
  • AKKARAJU SRINIVAS BUY 9,000
  • PATTERSON LEONE D BUY 9,000
  • AKKARAJU SRINIVAS J 19,408
  • AKKARAJU SRINIVAS J 14,937
  • AKKARAJU SRINIVAS J 10,657,028

Analyst estimates

Finnhub

What Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.

Low
$7.0
Mean
$18.71429
High
$25.0
Analysts
7
Recommendation distribution · period 2026-07-01
6
7
2
Revision trend (2026-04-01 → 2026-07-01): net 10 → 13 +3 (net = strong_buy+buy − sell−strong_sell)

SEC filings

The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.

FormFiled DescriptionAction
8-K 2026-07-17 8-K view ·
8-K 2026-07-06 8-K view ·
4 2026-06-04 4 view ·
4 2026-06-04 4 view ·
4 2026-06-04 4 view ·
4 2026-06-04 4 view ·
4 2026-06-04 4 view ·
4 2026-06-04 4 view ·
4 2026-06-04 4 view ·
8-K 2026-06-04 8-K view ·
4 2026-05-22 Insider transaction (Form 4) view ·
10-Q 2026-05-12 10-Q view ·
8-K 2026-05-12 8-K view ·
DEF 14A 2026-04-24 DEF 14A view ·
8-K 2026-04-10 8-K view ·
4 2026-03-23 4 view ·
4 2026-03-20 4 view ·
4 2026-03-20 4 view ·
4 2026-03-20 4 view ·
10-K 2026-03-17 10-K view ·
8-K 2026-03-17 8-K view ·
8-K 2026-03-09 8-K view ·
4 2026-02-17 Insider transaction (Form 4) view ·
4 2025-12-22 Insider transaction (Form 4) view ·
8-K 2025-12-18 8-K view ·
8-K 2025-12-17 8-K view ·
10-Q 2025-11-12 10-Q view ·
8-K 2025-11-12 8-K view ·
4 2025-11-03 4 view ·
8-K 2025-11-03 8-K view ·
10-Q 2025-08-13 10-Q view ·
8-K 2025-08-13 8-K view ·
8-K 2025-08-13 8-K view ·
DEF 14A 2025-07-01 DEF 14A view ·
8-K 2025-06-20 8-K view ·
10-Q 2025-05-14 10-Q view ·
8-K 2025-05-14 8-K view ·
8-K 2025-04-16 8-K view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
4 2025-04-11 4 view ·
8-K 2025-04-04 8-K view ·
4 2025-03-27 4 view ·
4 2025-03-18 4 view ·
4 2025-03-18 4 view ·
4 2025-03-18 4 view ·
4 2025-03-18 4 view ·
4 2025-03-18 4 view ·
4 2025-03-18 4 view ·
8-K 2025-03-18 8-K view ·
8-K 2025-03-12 8-K view ·
10-K 2025-03-07 10-K view ·

About KLRS

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Options picks · KLRS

ITM + OTM ideas from the latest scan

Loading…

Congress trades · KLRS

STOCK Act disclosures

Loading…

SEC filings & insiders · KLRS

EDGAR · live

Loading…

Holders · KLRS

Institutions & insider activity

Loading…